What Regulations Will Get Drones Ready to Deliver to Your Front Door?

Both pilots and companies are navigating a thin line between security and innovation. Host Grant Guillot talks with leaders, influencers, and experts across the drone industry to guide us through the complex web of technology and policy in the United States.

 

Every angle of the drone industry has a unique perspective. Organizations that bridge the gap between defense and commercial play a huge role, like FirePoint Innovation. The organization’s Technical Director, Paul Jonas, joined Drones in America host Grant Guillot to talk about FirePoint’s role in the field and more.

FirePoint is a partnership between Wichita State University and the U.S. Army Combat Capabilities Development Command, Aviation and Missile Center (DEVCOM AvMC). Their mission is to accelerate technology with all stakeholders—government regulators, defense, commercial sectors, and academics.

“I get to help an entire industry rather than one company.” -Paul Jonas

Jonas said, “We connect smart people inside and outside of defense. We are a research arm for the aviation industry, partnering with the Army around unmanned aircraft systems (UAS), which is a basic tenet of their modernization efforts.”

Jonas has 47 years in the aviation industry, serving as a chief engineer for companies like Beechcraft and Raytheon. He helped establish FirePoint, as well. “I get to help an entire industry rather than one company.”

Jonas and Guillot then discussed the new drone rules that go into effect on April 21, which allows for some flights over people and moving vehicles at night. “It’s a great leap forward. The lights for visibility and having the Remote ID in place, as well as specialized training, aren’t much different from commercial flights at night,” Jonas commented.

Jonas remarked that this move forward is also keeping a dialogue going between regulators and the industry, which is critical in seeing where the technology can go. This technology is currently taking the place of other processes, but once there is comfort with it, then the sky’s the limit. “We’ll be inventing new ways to use the technology,” he added.

See Previous Episodes of Drones In America Here

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More